











## Shingles Vaccination - Varicella Zoster Virus (VZV): - primary infection (varicella aka "chickenpox") characterized by vesicular lesions in different stage of development - Herpes Zoster-aka "shingle" characterized by unilateral vesicular eruption along dermatomal distribution - Decline in VZV-cell mediated immunity regarded as major precipitant for VZV reactivation - 30-40% adults>55 years do not have detectable VZV-specific T cell responses - Previous live attenuated vaccine ZVL (sold as Zostavax) - New recombinant vaccine RZV (sold as Shingrix) has higher efficacy - Requires 2 doses separated by at least 8 weeks. - About 11% experience side effects. Myalgia is most common. - For population older 50 there was 96.2% reduction in risk of HZ (while ZVL protection was only 51% in older than 60).









